Myriad Genetics Stock
Myriad Genetics Stock
With 9 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
As a result the target price of 10 € shows a very positive potential of 78.57% compared to the current price of 5.6 € for Myriad Genetics.
Criterium "EBIT growth" is seen as the biggest plus for Myriad Genetics stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Myriad Genetics in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Myriad Genetics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Myriad Genetics | - | 6.731% | -7.500% | -61.724% | 4.717% | -67.023% | -72.264% |
| Omnicell Inc. | 1.860% | 15.263% | 20.330% | 6.829% | 12.887% | -13.267% | -55.306% |
| Integer Hldg | 2.110% | 9.848% | 18.852% | -44.231% | 10.687% | 12.403% | 9.023% |
| Healthequity Inc. | -3.590% | 8.442% | 3.727% | -13.918% | 7.051% | 57.547% | 36.885% |
Comments
Myriad Genetics (NASDAQ:MYGN) had its price target lowered by analysts at Piper Sandler from $9.00 to $8.50. They now have an "overweight" rating on the stock.
Show more
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at Piper Sandler from $12.50 to $9.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $14.00 to $8.00. They now have a "buy" rating on the stock.
Show more
Ratings data for MYGN provided by MarketBeat